Essex Bio-Technology Balance Sheet Health
Financial Health criteria checks 6/6
Essex Bio-Technology has a total shareholder equity of HK$2.0B and total debt of HK$306.5M, which brings its debt-to-equity ratio to 15.2%. Its total assets and total liabilities are HK$3.0B and HK$950.3M respectively. Essex Bio-Technology's EBIT is HK$321.4M making its interest coverage ratio -46.3. It has cash and short-term investments of HK$600.6M.
Key information
15.2%
Debt to equity ratio
HK$306.54m
Debt
| Interest coverage ratio | -46.3x |
| Cash | HK$600.62m |
| Equity | HK$2.02b |
| Total liabilities | HK$950.33m |
| Total assets | HK$2.97b |
Recent financial health updates
Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13
Recent updates
Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement
Oct 09Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's
Aug 29Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Mar 21Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04
Aug 25Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
May 02Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055
Mar 30Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
Mar 13How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Feb 15Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?
Jan 25Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 04Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters
Nov 23Financial Position Analysis
Short Term Liabilities: 1061's short term assets (HK$1.4B) exceed its short term liabilities (HK$824.2M).
Long Term Liabilities: 1061's short term assets (HK$1.4B) exceed its long term liabilities (HK$126.1M).
Debt to Equity History and Analysis
Debt Level: 1061 has more cash than its total debt.
Reducing Debt: 1061's debt to equity ratio has reduced from 22.1% to 15.2% over the past 5 years.
Debt Coverage: 1061's debt is well covered by operating cash flow (103%).
Interest Coverage: 1061 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 01:03 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Essex Bio-Technology Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| null null | Guoyuan Securities (HK) Ltd |
| Stella Xing | Nomura Securities Co. Ltd. |